COVID-19 Vaccine

• CDC COVID-19 Vaccine Webinar Series (with CE) brief (15-20 minute) interactive modules that offer a real-world perspective on issues such as clinical and vaccine safety information, guidance for on-site clinic vaccination, and having conversations with vaccine recipients. Webinars
• CDC Vaccine Training Modules (with CE) – new Janssen module. Modules include a general overview of immunization practices, and Janssen, Pfizer and Moderna vaccine storage, handling, preparation, administration, and documentation. Modules

Standing webinars

• CDC COCA Webinars: Clinician Outreach and Communication Activity (COCA) Past COVID-19 topics include underlying medical conditions and severe COVID-19, vaccine safety and efficacy, and treating long COVID. Recorded webinars | Subscribe.
• CDC/IDSA COVID-19 Clinician Calls: Alternate Saturdays 12-1pm PST. Past webinars include post-COVID conditions, variants, vaccination, and COVID-19 outcomes in at-risk groups. Recorded webinars | Subscribe.
• AMA COVID-19 webinar series - What Physicians Need to Know: Live and archived webinars on COVID-19 vaccine and therapeutics Webinars

View recorded webinars

• CDC clinical considerations webpage with new sections on coadministration with other vaccines and vaccination of children and adolescents.
• CDC ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years MMWR. (5-14-21)
• CDPH Pfizer Vaccine Minor Consent Guidance Note: this is also for the public.
• CDC COVID-19 Vaccines for Children and Teens information for the public

DPH Resources (in English and Spanish)

• Paratransit/transit services for people with disabilities webpage
• Vaccine information for the public webpage: includes FAQs, vaccine and scams. Patients can also sign up to receive email newsletters with vaccine updates. Materials are available in multiple languages.
• After you get a vaccine  webpage and handouts: includes information on side effects, V-safe and mental health resources.
• When you are fully vaccinated webpages and handouts: explains what you can do after you are fully vaccinated, including when to wear a mask.
• Vaccine records  webpage: includes information on how to get a copy of a vaccination record from CAIR, and digital vaccination records.
• Promoting Vaccine Confidence checklist to help increase vaccine acceptance.

CDPH Resources

• Vaccine Benefits and Risks Fact Sheets one page summaries of the FDA EUA fact sheets
• Minor Consent for Pfizer vaccine guidance for providers and the public and template consent form

CDC Resources - Answering patients’ questions about COVID-19 vaccine:

• Engaging in Effective Vaccine Conversations webpage
• Tips and sample scripts of how to answer likely questions webpage
• Common Questions People May Ask Healthcare Professionals 2 page handout
• Patient FAQs
• CDC J&J vaccine update webpage, includes infographic with talking points for providers, and infographic for the public
• COVID-19 Vaccines for Children and Teens webpage for the public

FDA Resources

• Vaccine EUA fact sheets for recipients and caregivers Pfizer Moderna Janssen

• VRBPAC (10-26-21) Voted to recommend that the EUA for the Pfizer-BioNTech COVID-19 vaccine be expanded for use in children aged 5-11. Meeting notes and recording
• CDC COCA Call on Pediatric COVID-19 Vaccines recording and slides
• ACIP Meeting. Booster doses, effectiveness, and pregnancy (9-22-21 and 9-23-21) Slides
• CDC/IDSA COVID-19 Clinician Call: Vaccine Boosters and Q&A with CDC’s Vaccine Task Force This call will include discussions of immune response and COVID-19, perspectives from the Vaccines and Related Biological Products Advisory Committee, and ACIP recommendations and clinical considerations. Date and time: 9-25-21 at 12pm PT. Recording
• CDC COCA Call: What Clinicians Need to Know About the Latest CDC Recommendations for Pfizer-BioNTech COVID-19 Booster Vaccination Clinicians will learn about the vaccine booster recommendations, safety of booster dose, and clinical guidance for using the Pfizer-BioNTech COVID-19 booster vaccine. No registration required. Date and time: 9-28-21 at 11am-12pm PT. More info Slides
• CDC/IDSA COVID-19 Clinician Call: Vaccine Boosters and Q&A with CDC’s Vaccine Task Force (9-25-21) Includes information on immune response and COVID-19 and vaccination, perspectives from the Vaccines and Related Biological Products Advisory Committee, and ACIP recommendations and clinical considerations. Recording | Slides
• CDC COCA Call: Influenza vaccination and coadministration with COVID-19 vaccines (9-9-21) ACIP recommendations for 2021-2022 influenza vaccination and guidance for coadministration of these vaccines and COVID-19 vaccines. Free CME. Recording and Slides
• CDC COCA Call - Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People (8-17-21) Recording and Slides
• CDC/IDSA COVID-19 Clinician Call - Additional Vaccine Doses in the Immune-Compromised; the Latest on the Delta Variant, and Vaccination in Pregnant Women (8-14-21) Recording | Slides
• CDC/IDSA COVID-19 Clinician Call: More on the Delta Variant, CDC Masking Recommendations and Updates from ACIP (7-31-21) Discussions of vaccine efficacy against variants of COVID-19 and of risk of transmission of the Delta variant. Recording | Slides.
• Virtual ACIP Meeting CDC’s Advisory Committee on Immunization Practices (7-22-21) Included Guillain-Barré Syndrome (GBS) after vaccination with the Johnson & Johnson COVID-19 vaccine. Slides
• IAS-USA Webinar COVID-19 Vaccines and the Viral Variants: New Aspects of Vaccine Research (6-29-21)  International Antiviral Society-USA  - COVID-19 vaccines, vaccine development process, and clinical trials, including the latest emerging issues and the likely next phases of the pandemic. (CME available) Recording
• CDC/IDSA COVID-19 Clinician Call: Myocarditis after COVID-19 Vaccine; Plus Vaccine Q&A  (6-26-21) Case presentations, data, and discussions from the CDC Advisory Committee on Immunization Practices (ACIP). Recording | Slides
• Virtual ACIP Meeting (6-23-21) Topics included: myocarditis after mRNA vaccines VaST assessment, mRNA vaccines in adolescents and young adults - benefit-risk discussion; overview of data to inform recommendations for additional doses of vaccines Agenda | Slides
• Vaccines and Related Biological Products Advisory (VRPBAC) Committee Meeting  (6-10-21) Included CDC update on early safety data of Pfizer vaccination among adolescents and myocarditis and pericarditis following mRNA COVID-19 vaccination  Briefing documents, slides, and recording
• Becoming a COVID-19 Vaccinator - webinar for pediatricians from the American Academy of Pediatrics (5-20-21) Webinar
• CDC What Clinicians Need to Know About Pfizer-BioNTech COVID-19 Vaccination of Adolescents COCA Call (5-14-21) Webinar
• Providers of Pediatric Services: How to Enroll in the California COVID-19 Vaccination Program (5-11-21) CDPH and CMA informational session on the enrollment process and requirements for providers of pediatric services that are interested in participating in the state's COVID-19 vaccination program.  Slides | Recording
• COVID-19 in Pregnancy and Birth CMA webinar (5-11-21) View recording and download slides
• Johnson and Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome: Update for Clinicians. (4- 27-21) Recording | Slides
• CDC/IDSA COVID-19 Clinician Call Multisystem Inflammatory Syndrome in Adults (MIS-A); Plus ACIP Meeting Update (4-24-21) Recording, slides, and Q&A transcript
• COVID-19 Clinician Call: The Johnson & Johnson Vaccine: Current Situation & Anticipated Next Steps (4-17-21) Recording  
• CDC COCA webinar on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated J&J vaccine - including updated vaccine recommendations (4-15-21). Slides | Recording
• CDC/IDSA COVID-19 Clinician Call: COVID-19 in Pregnant Individuals; Plus Vaccine Q&A - Hosted in Partnership with ACOG. (4-10-21) Recording, slides, and Q&A transcript

Vaccine Administration Provider Line -Questions about vaccine distribution, storage and handling, and guidance on registering to receive the vaccine through the CDPH enrollment website.

• Monday through Friday, 8:00am- 5:00pm call 833-505-0761 or email COVIDVaccineReq@ph.lacounty.gov.

Vaccine Clinical Provider Line –Clinical questions about COVID-19 vaccines including but not limited to contraindications, precautions, side effects, post vaccination assessment

• Monday through Friday, 8:00am-5:00pm, call 213-240-7941. For time-sensitive questions after hours, call 213-974-1234 and ask for the on-call clinician

CDC/CISAvax (Clinical Immunization Safety Assessment Project) - Consults about COVID-19 vaccine safety. Healthcare providers can request a consultation from CISA COVIDvax for a complex COVID-19 vaccine safety question that is (1) about an individual patient residing in the United States or vaccine safety issue and (2) not readily addressed by CDC or Advisory Committee on Immunization Practices (ACIP) guidelines. CISA has vaccine safety subject matter experts in multiple specialties (e.g. ID, allergy/immunology, neurology, OB/GYN, pediatrics, geriatrics)

• Contact CDC_INFO: 800-CDC-INFO (800-232-4636) or online
• In case of an emergent clinical COVID-19 vaccine safety inquiry, healthcare providers can call the CDC Emergency Operations Center (EOC) Watch Desk at (770)-488-7100. The EOC Watch Desk will route emergency inquiries to the CISA COVIDvax on-call staff.

Medical professionals interested in supporting the COVID-19 response:

• Paid positions - contact the California COVID Health Corps
• Volunteer opportunities (including Medical Disaster Service Workers) - contact the City of Los Angeles - not currently accepting volunteers

Vaccine trial data, press releases, and information from the FDA, and more are below:

• LAC DPH COVID-19 Vaccine Eligibility Summary Table: LAC DPH has released a chart to help providers determine when to give COVID‐19 vaccine based on primary series, age, and/or health condition. The chart includes information on primary series/doses, additional doses for immunocompromised people, and booster doses. Table

Pfizer-BioNTech

• Frenck et al. Safety, Immunogenicity, and Efficacy of Pfizer Vaccine in Adolescents. NEJM 2021; online publication May 27.
• Walsh et al. Safety and immunogenicity of two RNA-Based COVID-19 vaccine candidates. NEJM 2020; online publication Oct 14.
• Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints Press Release 11-18-20
• Phase 3 trial information 12-10-20 New England Journal of Medicine Safety and Efficacy of the BNT162b2 Covid-19 Vaccine  Editorial  Video summary
• Pfizer vaccine: CDC webpage  FDA webpage (includes fact sheets for Healthcare Providers and  Recipients and Caregivers in 20 languages)
• Pfizer vaccine efficacy at 6 months. Pfizer reported the vaccine to be highly effective against symptomatic cases up to 6 months after the second dose, and 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent. Press release 4-1-21
• Pfizer vaccine efficacy in 12-15 year-olds The study demonstrated 100% efficacy in 12-15 year-olds. The company plans to submit an EUA application. 3-31-21 Press release
• CDC recommends use of Pfizer COVID-19 vaccine in 12-15-yearolds(5-12-21) The CDC’s ACIP voted unanimously to recommend giving the Pfizer/BioNTech COVID-19 vaccine to children as young as 12 years of age. The CDC now recommends that this vaccine be used among this population, and providers may begin vaccinating them right away. See CDC Director Statement and ACIP Presentation Slides.

Moderna

• Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June Press Release 5-25-21
• Jackson et al. An mRNA Vaccine against SARS-CoV-2-Preliminary report. NEJM 2020;20:1920-1931.
• Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate Press Release 11-30-20
• Moderna vaccine: CDC webpage  FDA webpage (includes fact sheets for Healthcare Providers and  Recipients and Caregivers in multiple languages)

Janssen (Johnson & Johnson)

• Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. NEJM 2021 online publication April 21. One page research summary.
• Janssen COVID-19 Vaccine FDA webpage includes fact sheets (for healthcare providers and for patients and caregivers), FAQs, letter of authorization and decision memo
• Janssen COVID-19 Vaccine (Johnson & Johnson) CDC Product Information webpage
• ACIP Meeting (Feb 28-March 1, 2021) Slides Webcast
• FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting 2-26-21 Agenda and Materials, FDA Briefing Document,  Janssen Briefing Document and Addendum
• Press Releases: Interim Analysis of Phase 3 Clinical Data 1-29-21 See press releases from Johnson & Johnson and the NIH.
• ACIP J&J vaccine meetings - decision to extend pause in vaccine administration 4-14-2 Slides and to lift pause 4-23-21 Slides Statement.